Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 17 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Travere Therapeutics Inc | TVTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.39 | 07:12:54 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.39 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 6 | 17 | - | 5.12 - 22.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:07:20 | 3 | $ 5.45 | USD |
Travere Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 410.17M | 76.10M | - | 145.24M | -111.4M | -1.46 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Travere Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TVTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.73 | 5.96 | 5.12 | 5.59 | 1,614,467 | -0.34 | -5.93% |
| 1 Month | 7.71 | 7.77 | 5.12 | 6.31 | 1,375,130 | -2.32 | -30.09% |
| 3 Months | 8.55 | 9.03 | 5.12 | 7.38 | 1,202,196 | -3.16 | -36.96% |
| 6 Months | 7.00 | 10.27 | 5.12 | 7.63 | 1,442,174 | -1.61 | -23.00% |
| 1 Year | 20.99 | 22.75 | 5.12 | 10.49 | 1,447,263 | -15.60 | -74.32% |
| 3 Years | 24.29 | 31.65 | 5.12 | 16.97 | 1,084,106 | -18.90 | -77.81% |
| 5 Years | 25.15 | 33.0899 | 5.12 | 17.63 | 1,017,464 | -19.76 | -78.57% |
Travere Therapeutics Description
| Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease. |
